Literature DB >> 11104737

Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion.

P R Sage1, I S de la Lande, I Stafford, C L Bennett, G Phillipov, J Stubberfield, J D Horowitz.   

Abstract

BACKGROUND: The basis for progressive attenuation of the effects of organic nitrates during long-term therapy (nitrate tolerance) remains controversial; proposed mechanisms include impaired nitrate bioconversion resulting in decreased release of nitric oxide (NO) from nitrates and/or increased NO clearance through a reaction with incrementally generated superoxide (O(2)(-)). METHODS AND
RESULTS: Patients undergoing elective coronary artery bypass were randomized to receive 24 hours of intravenously infused nitroglycerin (NTG; nitrate group) or no nitrate therapy (control group). Discarded segments of the internal mammary artery and saphenous vein were used to examine (1) vascular responsiveness to NTG, sodium nitroprusside, and the calcium ionophore A23187; (2) bioconversion of NTG to 1,2- and 1,3-glyceryl dinitrate; and (3) the generation of O(2)(-). Responses to NTG were reduced 3- to 5-fold in vessels from the nitrate group compared with control vessels (P:<0. 01 for both types of segments), whereas responses to sodium nitroprusside and A23187 were unchanged. Tissue content of 1, 2-glyceryl dinitrate was lower (P:=0.012) in the saphenous veins from the nitrate group than in those from the control group. O(2)(-) generation was greater (P:<0.01) in internal mammary artery samples from the nitrate group than in those from the control group. However, incremental O(2)(-) generation induced by an inhibitor of superoxide dismutase did not affect NTG responses.
CONCLUSIONS: NTG tolerance in patients with coronary artery disease is nitrate-specific and is associated with evidence of impaired NTG bioconversion. Tolerance was associated with incremental O(2)(-) generation, but short-term elevation of O(2)(-) did not affect NTG responsiveness, suggesting increased NO clearance by O(2)(-) has a minimal contribution to tolerance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104737     DOI: 10.1161/01.cir.102.23.2810

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  39 in total

1.  Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway.

Authors:  Anne Otto; Jeanine Fontaine; Eric Tschirhart; David Fontaine; Guy Berkenboom
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  After 130 years, the molecular mechanism of action of nitroglycerin is revealed.

Authors:  Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

3.  Arginase II inhibition prevents nitrate tolerance.

Authors:  S M L Khong; K L Andrews; N N Huynh; K Venardos; A Aprico; D L Michell; M Zarei; K T Moe; G J Dusting; D M Kaye; J P F Chin-Dusting
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 4.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

5.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

6.  Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration.

Authors:  Kenichi Yamahara; Hiroshi Itoh; Tae-Hwa Chun; Yoshihiro Ogawa; Jun Yamashita; Naoki Sawada; Yasutomo Fukunaga; Masakatsu Sone; Takami Yurugi-Kobayashi; Kazutoshi Miyashita; Hirokazu Tsujimoto; Hyun Kook; Robert Feil; David L Garbers; Franz Hofmann; Kazuwa Nakao
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-05       Impact factor: 11.205

7.  An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation.

Authors:  Zhiqiang Chen; Matthew W Foster; Jian Zhang; Lan Mao; Howard A Rockman; Toshihiro Kawamoto; Kyoko Kitagawa; Keiichi I Nakayama; Douglas T Hess; Jonathan S Stamler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

8.  Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite.

Authors:  Abdul R Maher; Sayqa Arif; Melanie Madhani; Khalid Abozguia; Ibrar Ahmed; Bernadette O Fernandez; Martin Feelisch; A G O'Sullivan; Arthur Christopoulos; Aaron L Sverdlov; Doan Ngo; Rustem Dautov; Philip E James; John D Horowitz; Michael P Frenneaux
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Chronic nitrates blunt the effects of not only nitric oxide but also natriuretic peptides in cardiac myocytes.

Authors:  Tao Tan; Qihang Zhang; Chukwuma Anyadike; Peter M Scholz; Harvey R Weiss
Journal:  Pharmacol Res       Date:  2007-03-31       Impact factor: 7.658

10.  Characterization of the East Asian variant of aldehyde dehydrogenase-2: bioactivation of nitroglycerin and effects of Alda-1.

Authors:  Matteo Beretta; Antonius C F Gorren; M Verena Wenzl; Robert Weis; Michael Russwurm; Doris Koesling; Kurt Schmidt; Bernd Mayer
Journal:  J Biol Chem       Date:  2009-11-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.